This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
There has been a lot of talk recently about the biosimilars marketplace and what role biosimilars play in reducing health care costs. We’re here to set the record straight about how these medicines are reshaping America’s health care landscape and improving patient and provider choice.
An analysis of data from more than 640,000 people with diabetes recorded between 2015-2020 is providing new insight into what study investigators are calling "troubling" trends in the incidence of CKD in the face a growing diabetes epidemic.
Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.
US Preventive Services Task Force hasn't endorsed screening for atrial fibrillation. Findings from these two studies might factor into a reconsideration.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
A researcher suggests that novel immune modulating cancer therapies like cancer vaccines can be more effective and safer alternative to previous cancer immunotherapies.
A researcher suggests that novel immune modulating cancer therapies like cancer vaccines can be more effective and safer alternative to previous cancer immunotherapies.
New findings reveal an out-of-pocket cost gap between brand-name and generic prescriptions. To address this gap, GoodRx is partnering with pharmaceutical companies to improve cost transparency and communication between patients and providers.
Research at Boston University that involved testing a lab-made hybrid version of the SARS-CoV-2 virus is garnering heated headlines alleging the scientists involved could have unleashed a new pathogen. There is no evidence the work, performed under biosecurity level 3 precautions in BU’s National Emerging Infectious Diseases Laboratories, was conducted improperly or unsafely.
According to a recent survey conducted by PPD, part of Thermo Fisher Scientific, 98% of drug developers report that, in the wake of COVID-19, they have embraced a wealth of new strategies across the entire clinical trial lifecycle – from adaptive trial design to big data. Find out how to apply these trends to your innovative clinical programs.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Before the Covid-19 pandemic emerged, influenza trackers would begin reading tea leaves around this time of the year, looking for signs of whether there would be an early start to the flu season in the northern hemisphere and which of the various flu viruses might be responsible for the most cases over the coming winter. Flu transmission has been low since the start of the pandemic , but an odd spurt of activity in April, May, and even early June of 2022 — which coincided with the onset o
The next big Alzheimer’s disease study readout is almost here. Roche is nearing the completion of a pair of clinical trials involving its experimental treatment called gantenerumab. The Swiss pharma giant will announce results from the studies within the next six weeks.
When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. Their success led to the discovery of an entirely new principle for cancer therapy – the field of immuno-oncology – one that is now a mainstay of cancer treatment, changing the way these diseases can be managed.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
The University of Pennsylvania’s Division of Renal-Electrolyte and Hypertension recently made a quiet update to its history web page : it removed all references to its former co-chief, Dr. Stanley Goldfarb. For several years, Goldfarb has been a vocal critic of considering social determinants of health, racism, and anything else he considers too “woke” in medical education or health care at large.
Milestone Pharmaceuticals said Monday that an experimental nasal-spray medicine acted quickly to treat people experiencing episodes of a rapid but non-fatal heart rate — more than doubling the conversion to normal heart rhythm and achieving the primary goal of a late-stage clinical trial. The medicine, called etripamil , is meant to treat people with paroxysmal supraventricular tachycardia, or PSVT, a condition characterized by episodes of rapid heartbeat that suddenly start and stop.
Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. Elinzanetant is already being tested in the OASIS trials for VMS associated with menopause – an indication in which Bayer is in a head-to-head race with Astellas and its fezolinetant drug candidate – and breast cancer could represent a sizeable additional patient population for the drug.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The Department of Justice filed a new lawsuit against Cigna Monday, alleging the health insurance company overcharged the federal government by purposefully inflating how sick its Medicare Advantage members were. The decision is a change of heart from federal prosecutors, who originally declined to intervene in the whistleblower case back in 2020.
Included in this issue: PATENTS. Patents: a necessary evil? David Elder, David P Elder Consultancy. MICROBIOLOGY. Pharma’s green mission: trends in bacterial endotoxin testing. Hannah Balfour. Lindsey Silva, Carmen Marín Delgado de Robles, Viviane Grunert da Fonseca and Evelyn Der, Roche Group. QA/QC. An Annex 1 and Pharma 4.0 perspective on water quality.
Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No surprise, then, that his next effort has already raised at least $473 million in funding from private investors even before telling the public what, exactly, it is working on. Treeline Biosciences, the new venture by Bilenker and Jeffrey Engelman, formerly Novartis’s top cancer researcher, has hired more than 130 people across three research sites in little more than a year, according to a co
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that all-too-predictable routine of online meetings, calls, and deadlines has returned. But what can you do? The world, such as it is, keeps spinning. So time to give it a nudge in a better direction by firing up the coffee kettle to brew another cup of stimulation.
Drugmakers’ powerhouse lobby did not exactly make good on its early August threat to hold Democrats “accountable” this fall after the caucus voted to let the government negotiate drug prices. The Pharmaceutical Research and Manufacturers of America’s political action committee put $2,000 towards the New Democrat Coalition Action Fund on Aug. 22, just weeks after every member voted for the sweeping Inflation Reduction Act that includes an unprecedented move to let the
Novo Nordisk has concluded the acquisition of all outstanding shares of common stock of clinical-stage biopharmaceutical company Forma Therapeutics for $20 for each share in cash or a deal totalling $1.1bn. In September, Novo Nordisk entered a definitive agreement to acquire Forma. With the conclusion of the merger, Forma became Novo Nordisk’s fully-owned subsidiary. .
The European Medicines Agency’s human medicines committee ( CHMP ) has recommended the use of Takeda’s Dengue Tetravalent Vaccine (live, attenuated), to prevent disease caused by dengue virus serotypes 1, 2, 3 and 4 in people from four years of age to 45+. This recommendation marks the first time the CHMP has simultaneously reviewed applications for EU-aimed medicine under both the centralised procedure and the EMA’s ‘EU-Medicines for all’ (EU-M4all) programme for non-EU countries.
US biopharma company Enterin Inc. and Parkinson’s UK’s drug development and discovery division, Parkinson’s Virtual Biotech , will collaborate on a new Phase II trial to study the effects of the drug ENT-01 on Parkinson’s Disease (PD)-associated dementia. . The partnership will build on research from Enterin’s randomised, placebo-controlled Phase II trial earlier this year.
Former Assistant Secretary for Health in the Department of Health and Human Services and member of the White House Coronavirus Task Force demonstrated tremendous leadership on the front lines of the COVID-19 response.
A Certified Nurse-Midwife (CNM) is a healthcare provider that delivers care to women throughout all stages of their lives. While they are similar in some ways to Labor & Delivery nurses (L&D) and OBGYNs, CNMs have a unique role in the lives of women. What is a Certified Nurse-Midwife, and what steps do you need to take to become a CNM? What is the Role of a Certified Nurse-Midwife?
The Omicron BA.4/BA.5-adapted-bivalent COVID-19 vaccine demonstrated a substantial increase in antibody response above pre-booster levels. The Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine showed a substantial increase in neutralising antibody response according to a press release by the joint manufacturers Pfizer and BioNTech. The findings come from a Phase 2/3 clinical trial evaluating the safety, tolerability, and immunogenicity of the companies’ bivalent vaccine.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content